全文获取类型
收费全文 | 42918篇 |
免费 | 3645篇 |
国内免费 | 479篇 |
专业分类
耳鼻咽喉 | 277篇 |
儿科学 | 646篇 |
妇产科学 | 764篇 |
基础医学 | 2282篇 |
口腔科学 | 635篇 |
临床医学 | 9563篇 |
内科学 | 3422篇 |
皮肤病学 | 238篇 |
神经病学 | 848篇 |
特种医学 | 580篇 |
外国民族医学 | 3篇 |
外科学 | 4360篇 |
综合类 | 6728篇 |
现状与发展 | 3篇 |
一般理论 | 3篇 |
预防医学 | 10872篇 |
眼科学 | 212篇 |
药学 | 3528篇 |
120篇 | |
中国医学 | 692篇 |
肿瘤学 | 1266篇 |
出版年
2024年 | 56篇 |
2023年 | 848篇 |
2022年 | 1355篇 |
2021年 | 2192篇 |
2020年 | 2673篇 |
2019年 | 1699篇 |
2018年 | 1597篇 |
2017年 | 1696篇 |
2016年 | 1732篇 |
2015年 | 1698篇 |
2014年 | 3908篇 |
2013年 | 3568篇 |
2012年 | 3225篇 |
2011年 | 3179篇 |
2010年 | 2640篇 |
2009年 | 2238篇 |
2008年 | 2250篇 |
2007年 | 1917篇 |
2006年 | 1775篇 |
2005年 | 1367篇 |
2004年 | 1187篇 |
2003年 | 889篇 |
2002年 | 668篇 |
2001年 | 478篇 |
2000年 | 381篇 |
1999年 | 312篇 |
1998年 | 285篇 |
1997年 | 209篇 |
1996年 | 177篇 |
1995年 | 117篇 |
1994年 | 104篇 |
1993年 | 104篇 |
1992年 | 70篇 |
1991年 | 83篇 |
1990年 | 38篇 |
1989年 | 42篇 |
1988年 | 37篇 |
1987年 | 34篇 |
1986年 | 27篇 |
1985年 | 52篇 |
1984年 | 31篇 |
1983年 | 27篇 |
1982年 | 19篇 |
1981年 | 20篇 |
1980年 | 16篇 |
1979年 | 5篇 |
1978年 | 9篇 |
1977年 | 3篇 |
1976年 | 3篇 |
1973年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 265 毫秒
1.
2.
3.
4.
Syed M. Gilani Muhammad Khan Andrea Barbieri Manju L. Prasad 《Diagnostic Histopathology》2021,27(6):263-271
Anaplastic thyroid carcinoma (ATC) is an aggressive thyroid malignancy with high mortality rate. This malignancy arises in thyroid follicular cells either denovo or with an associated differentiated thyroid carcinoma component. Clinically, it usually presents as a rapidly enlarging mass, pain and locally compressive symptoms. Histopathologic variability and heterogeneity often pose diagnostic challenges, especially in scant and paucicellular specimens. This article describes the clinical, histopathologic and molecular features of ATC and also addresses the associated diagnostic limitations and challenges. 相似文献
5.
6.
《Journal of Radiology Nursing》2022,41(2):123-128
ObjectiveThe objective of this study was to reduce errors in a pathologic specimen with the help of a protocol systematizing the pathology specimen management process in the operating room.Materials and methodThis quasi-experimental study was carried out in the operating room unit of a research and training hospital. A protocol systematizing the process of specimen management in secure surgical pathology and prepared in light of the current literature was used as an intervention, and the effectiveness of the protocol was tested.ResultsIt was determined that the rate of adverse events decreased from .3226% (68 of 21,078) to .032% (6 of 18,706) after the protocol systematizing the surgical pathology specimen management process prepared by the researchers, and the protocol was found to be effective by 90% (P = .03).ConclusionBased on the data obtained in this study, we recommend the use of a pathologic specimen management protocol in the operating room. 相似文献
7.
8.
9.
Michael Staehler Peter J. Goebell Lothar Müller Till-Oliver Emde Natalie Wetzel Lisa Kruggel Martina Jänicke Norbert Marschner the RCC-Registry Group 《International journal of cancer. Journal international du cancer》2020,146(5):1307-1315
Non-clear cell renal cell carcinoma is a very rare malignancy that includes several histological subtypes. Each subtype may need to be addressed separately regarding prognosis and treatment; however, no Phase III clinical trial data exist. Thus, treatment recommendations for patients with non-clear cell metastatic RCC (mRCC) remain unclear. We present first prospective data on choice of first- and second-line treatment in routine practice and outcome of patients with papillary mRCC. From the prospective German clinical cohort study (RCC-Registry), 99 patients with papillary mRCC treated with systemic first-line therapy between December 2007 and May 2017 were included. Prospectively enrolled patients who had started first-line treatment until May 15, 2016, were included into the outcome analyses (n = 82). Treatment was similar to therapies used for clear cell mRCC and consisted of tyrosine kinase inhibitors, mechanistic target of rapamycin inhibitors and recently checkpoint inhibitors. Median progression-free survival from start of first-line treatment was 5.4 months (95% confidence interval [CI], 4.1–9.2) and median overall survival was 12.0 months (95% CI, 8.1–20.0). At data cutoff, 73% of the patients died, 6% were still observed, 12% were lost to follow-up, and 9% were alive at the end of the individual 3-year observation period. Despite the lack of prospective Phase III evidence in patients with papillary mRCC, our real-world data reveal effectiveness of systemic clear cell mRCC therapy in papillary mRCC. The prognosis seems to be inferior for papillary compared to clear cell mRCC. Further studies are needed to identify drivers of effectiveness of systemic therapy for papillary mRCC. 相似文献
10.